A carregar...
Cost–Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I
BACKGROUND: Tyrosinemia type I is a rare but severe genetic metabolic disorder. Nitisinone combined with a diet low in tyrosine and phenylalanine became first-line therapy in 1994. OBJECTIVES: To estimate the direct medical costs of health care services related to the treatment of tyrosinemia type I...
Na minha lista:
| Publicado no: | Can J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Canadian Society of Hospital Pharmacists
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485508/ https://ncbi.nlm.nih.gov/pubmed/26157182 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|